7 June 2023 in Annals of the Rheumatic Diseases
Background Psoriasis is a chronic, multisystem inflammatory disease with predominantly skin and joint involvement. The interleukin-(IL-)17 axis plays a vital role in the development of psoriasis. Secukinumab (Cosentyx) is a fully human monoclonal antibody that selectively targets IL-17A for the treatment of adult patients with psoriasis[1]. Objectives This study aimed to systematically evaluate the efficacy and safety of secukinumab therapy in psoriasis. Methods Eight databases (PubMed, Web of Science, Embase, Cochrane Library, Web of Knowledge, MEDLINE, Clinical Trials.gov, and FDA.gov) were searched for studies on secukinumab treatment of psoriasis published from the date of establishment of the database to January 3, 2022. A random effect model was used to conduct a meta-analysis of the efficacy and safety of abatacept in patients with RA using (Stata 12.0). Results A total of 27 studies with a total of 4470 patients were included. After receiving secukinumab therapy for 12 weeks, The response rate of PASI 75 was 82.2% (95% CI 0.766–0.879,p<0.01), PASI 90 was 66.3%(95% CI 0.609–0.718,p<0.01), and PASI 100 was 42% (95% CI 0.343–0.497,p<0.01). The results showed that more than 80% of patients achieved skin lesion removal in 12 weeks. Considering PGA 0/1 as the secondary endpoint. The percentage of patients who achieved a PGA score of 0 or 1 was 72.3% at 12 weeks (95% CI 0.658–0.788,p=0.005). As for the safety, the incidence of adverse events was 63.7%. Infection is the main adverse effects, with rates of 19.4%. Most of the adverse events were mild and recovered quickly after discontinuation. (Figure 1) Conclusion Secukinumab is effective in patients with psoriasis and is generally well tolerated, and thus represents a useful treatment alternative to TNFi and other bDMARDs in adult patients with psoriasis. Reference [1]Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4):483-94. Available evidence including patients with psoriasis treated with secukinumab. Efficacy of Secukinumab in patients with psoriasis (A) PASI 75 (B) PASI 90 (C) PASI 100 (D) PGA score of 0 or 1 Acknowledgements: NIL. Disclosure of Interests None Declared.